Adaptive Autonomic and Neuroplastic Control in Diabetic Neuropathy:
A Narrative Review

Francesca      Marsili; Paul      Potgieter; Corlius   Fourie   Birkill
doi:10.2174/0115733998253213231031050044
Abstract

Background: Type 2 diabetes mellitus (T2DM) is a worldwide socioeconomic burden, and is accompanied by a variety of metabolic disorders, as well as nerve dysfunction referred to as diabetic neuropathy (DN). Despite a tremendous body of research, the pathogenesis of DN remains largely elusive. Currently, two schools of thought exist regarding the pathogenesis of diabetic neuropathy: a) mitochondrial-induced toxicity, and b) microvascular damage. Both mechanisms signify DN as an intractable disease and, as a consequence, therapeutic approaches treat symptoms with limited efficacy and risk of side effects.
Objective: Here, we propose that the human body exclusively employs mechanisms of adaptation to protect itself during an adverse event. For this purpose, two control systems are defined, namely the autonomic and the neural control systems. The autonomic control system responds via inflammatory and immune responses, while the neural control system regulates neural signaling, via plastic adaptation. Both systems are proposed to regulate a network of temporal and causative connections which unravel the complex nature of diabetic complications.
Results: A significant result of this approach infers that both systems make DN reversible, thus opening the door to novel therapeutic applications.
[1]
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes-global burden of disease and forecasted trends. J Epidemiol Glob Health  2019; 10(1): 107-11.
 [http://dx.doi.org/10.2991/jegh.k.191028.001] [PMID: 32175717]

[2]
International Diabetes Federation. IDF Diabetes Atlas.  (10th ed.),  2021. Available from: https://www.diabetesatlas.org

[3]
Bo A, Thomsen RW, Nielsen JS, et al. Early‐onset type 2 diabetes: Age gradient in clinical and behavioural risk factors in 5115 persons with newly diagnosed type 2 diabetes-results from the DD2 study. Diabetes Metab Res Rev  2018; 34(3): e2968.
 [http://dx.doi.org/10.1002/dmrr.2968] [PMID: 29172021]

[4]
Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care  2009; 32 (Suppl. 2): S151-6.
 [http://dx.doi.org/10.2337/dc09-S301] [PMID: 19875543]

[5]
Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev  2013; 93(1): 137-88.
 [http://dx.doi.org/10.1152/physrev.00045.2011] [PMID: 23303908]

[6]
Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep  2019; 19(10): 86.
 [http://dx.doi.org/10.1007/s11892-019-1212-8] [PMID: 31456118]

[7]
Kobayashi M, Zochodne DW. Diabetic neuropathy and the sensory neuron: New aspects of pathogenesis and their treatment implications. J Diabetes Investig  2018; 9(6): 1239-54.
 [http://dx.doi.org/10.1111/jdi.12833] [PMID: 29533535]

[8]
Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers  2019; 5(1): 41.
 [http://dx.doi.org/10.1038/s41572-019-0092-1] [PMID: 31197153]

[9]
Gundogdu BM. Diabetic peripheral neuropathy: An update on pathogenesis and management. Curr Neurol Neurosci Rep  2006; 6(1): 1-4.
 [http://dx.doi.org/10.1007/s11910-996-0001-3] [PMID: 16469264]

[10]
Rahman MS, Hossain KS, Das S, et al. Role of insulin in health and disease: An update. Int J Mol Sci  2021; 22(12): 6403.
 [http://dx.doi.org/10.3390/ijms22126403] [PMID: 34203830]

[11]
Ohishi M. Hypertension with diabetes mellitus: Physiology and pathology. Hypertens Res  2018; 41(6): 389-93.
 [http://dx.doi.org/10.1038/s41440-018-0034-4] [PMID: 29556093]

[12]
Clark MG, Wallis MG, Barrett EJ, et al. Blood flow and muscle metabolism: A focus on insulin action. Am J Physiol Endocrinol Metab  2003; 284(2): E241-58.
 [http://dx.doi.org/10.1152/ajpendo.00408.2002] [PMID: 12531739]

[13]
Limberg JK, Soares RN, Power G, et al. Hyperinsulinemia blunts sympathetic vasoconstriction: A possible role of β-adrenergic activation. Am J Physiol Regul Integr Comp Physiol  2021; 320(6): R771-9.
 [http://dx.doi.org/10.1152/ajpregu.00018.2021] [PMID: 33851554]

[14]
Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction. Circulation  2006; 113(15): 1888-904.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.105.563213] [PMID: 16618833]

[15]
Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation  1997; 96(11): 4104-13.
 [http://dx.doi.org/10.1161/01.CIR.96.11.4104] [PMID: 9403636]

[16]
Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: Mechanisms, bioenergetics, and pain. Neuron  2017; 93(6): 1296-313.
 [http://dx.doi.org/10.1016/j.neuron.2017.02.005] [PMID: 28334605]

[17]
Hadi HAR, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag  2007; 3(6): 853-76.
 [PMID: 18200806]

[18]
Zhou MS, Schulman IH, Zeng Q. Link between the renin–angiotensin system and insulin resistance: Implications for cardiovascular disease. Vasc Med  2012; 17(5): 330-41.
 [http://dx.doi.org/10.1177/1358863X12450094] [PMID: 22814999]

[19]
Rask-Madsen C, King GL. Vascular complications of diabetes: Mechanisms of injury and protective factors. Cell Metab  2013; 17(1): 20-33.
 [http://dx.doi.org/10.1016/j.cmet.2012.11.012] [PMID: 23312281]

[20]
Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci  2011; 1243(1): 88-102.
 [http://dx.doi.org/10.1111/j.1749-6632.2011.06320.x] [PMID: 22211895]

[21]
Pongratz G, Straub RH. The sympathetic nervous response in inflammation. Arthritis Res Ther  2014; 16(6): 504.
 [http://dx.doi.org/10.1186/s13075-014-0504-2] [PMID: 25789375]

[22]
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta Mol Cell Res  2011; 1813(5): 878-88.
 [http://dx.doi.org/10.1016/j.bbamcr.2011.01.034] [PMID: 21296109]

[23]
Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology  2018; 26(3): 685-98.
 [http://dx.doi.org/10.1007/s10787-018-0458-0] [PMID: 29508109]

[24]
Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochimica et Biophysica Acta (BBA) -. Molecular Cell Research  2016; 1863(6): 1218-27.

[25]
Cox AA, Sagot Y, Hedou G, et al. Low-dose pulsatile interleukin-6 as a treatment option for diabetic peripheral neuropathy. Front Endocrinol  2017; 8: 89.
 [http://dx.doi.org/10.3389/fendo.2017.00089] [PMID: 28512447]

[26]
Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget  2018; 9(6): 7204-18.
 [http://dx.doi.org/10.18632/oncotarget.23208] [PMID: 29467962]

[27]
Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The role of inflammation in diabetes: Current concepts and future perspectives. Eur Cardiol  2019; 14(1): 50-9.
 [http://dx.doi.org/10.15420/ecr.2018.33.1] [PMID: 31131037]

[28]
Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: Role in type 2 diabetes. Clin Chim Acta  2012; 413(15-16): 1163-70.
 [http://dx.doi.org/10.1016/j.cca.2012.03.021] [PMID: 22521751]

[29]
Lyra e Silva NM, Gonçalves RA, Pascoal TA, et al. Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease. Transl Psychiatry  2021; 11(1): 251.
 [http://dx.doi.org/10.1038/s41398-021-01349-z] [PMID: 33911072]

[30]
Zhou J, Zhou S. Inflammation: Therapeutic targets for diabetic neuropathy. Mol Neurobiol  2014; 49(1): 536-46.
 [http://dx.doi.org/10.1007/s12035-013-8537-0] [PMID: 23990376]

[31]
Feigerlová E, Battaglia-Hsu SF. IL-6 signaling in diabetic nephropathy: From pathophysiology to therapeutic perspectives. Cytokine Growth Factor Rev  2017; 37: 57-65.
 [http://dx.doi.org/10.1016/j.cytogfr.2017.03.003] [PMID: 28363692]

[32]
Lieb DC, Parson HK, Mamikunian G, Vinik AI. Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Exp Diabetes Res  2012; 2012: 1-8.
 [http://dx.doi.org/10.1155/2012/878760] [PMID: 22110481]

[33]
Weitz J, Diaz RR, Almaca J, Makhmutova M, Caicedo A. Anti-inflammatory cholinergic signals inhibit islet resident macrophage responses to ATP in living pancreatic tissue slices. Diabetes  2018; 67(Supplement_1)
 [http://dx.doi.org/10.2337/db18-197-OR]

[34]
White UA, Stephens JM. The gp130 receptor cytokine family: Regulators of adipocyte development and function. Curr Pharm Des  2011; 17(4): 340-6.
 [http://dx.doi.org/10.2174/138161211795164202] [PMID: 21375496]

[35]
Qu D, Liu J, Lau CW, Huang Y. IL-6 in diabetes and cardiovascular complications. Br J Pharmacol  2014; 171(15): 3595-603.
 [http://dx.doi.org/10.1111/bph.12713] [PMID: 24697653]

[36]
Montgomery A, Tam F, Gursche C, et al. Overlapping and distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells. Am J Physiol Cell Physiol  2021; 320(4): C554-65.
 [http://dx.doi.org/10.1152/ajpcell.00323.2020] [PMID: 33471622]

[37]
Zhang XL, Topley N, Ito T, Phillips A. Interleukin-6 regulation of transforming growth factor (TGF)-β receptor compartmentalization and turnover enhances TGF-β1 signaling. J Biol Chem  2005; 280(13): 12239-45.
 [http://dx.doi.org/10.1074/jbc.M413284200] [PMID: 15661740]

[38]
Robinson R, Srinivasan M, Shanmugam A, et al. Interleukin-6 trans-signaling inhibition prevents oxidative stress in a mouse model of early diabetic retinopathy. Redox Biol  2020; 34: 101574.
 [http://dx.doi.org/10.1016/j.redox.2020.101574] [PMID: 32422539]

[39]
Campbell IL, Erta M, Lim SL, et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci  2014; 34(7): 2503-13.
 [http://dx.doi.org/10.1523/JNEUROSCI.2830-13.2014] [PMID: 24523541]

[40]
Recasens M, Almolda B, Pérez-Clausell J, Campbell IL, González B, Castellano B. Chronic exposure to IL-6 induces a desensitized phenotype of the microglia. J Neuroinflammation  2021; 18(1): 31.
 [http://dx.doi.org/10.1186/s12974-020-02063-1] [PMID: 33482848]

[41]
Lamagna C, Aurrand-Lions M, Imhof BA. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol  2006; 80(4): 705-13.
 [http://dx.doi.org/10.1189/jlb.1105656] [PMID: 16864600]

[42]
Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: Negative, as well as positive, regulators of immunity. Nat Rev Immunol  2008; 8(6): 478-86.
 [http://dx.doi.org/10.1038/nri2327] [PMID: 18483499]

[43]
Castilla MÁ, Caramelo C, Gazapo RM, et al. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci  2000; 67(9): 1003-13.
 [http://dx.doi.org/10.1016/S0024-3205(00)00693-7] [PMID: 10954034]

[44]
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care  2003; 26(5): 1553-79.
 [http://dx.doi.org/10.2337/diacare.26.5.1553] [PMID: 12716821]

[45]
Xiao J, Li J, Cai L, Chakrabarti S, Li X. Cytokines and diabetes research. J Diabetes Res  2014; 2014: 1-2.
 [http://dx.doi.org/10.1155/2014/920613] [PMID: 24551859]

[46]
Kim H, Zamel R, Bai XH, Liu M. PKC activation induces inflammatory response and cell death in human bronchial epithelial cells. PLoS One  2013; 8(5): e64182.
 [http://dx.doi.org/10.1371/journal.pone.0064182] [PMID: 23691166]

[47]
Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. Semin Immunol  2014; 26(3): 237-45.
 [http://dx.doi.org/10.1016/j.smim.2014.02.009] [PMID: 24647229]

[48]
Yung JHM, Giacca A. Role of c-Jun N-terminal Kinase (JNK) in obesity and type 2 Diabetes. Cells  2020; 9(3): 706.
 [http://dx.doi.org/10.3390/cells9030706] [PMID: 32183037]

[49]
Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab  2012; 16 (Suppl. 1): S27-36.
 [PMID: 22701840]

[50]
Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes Metab Res Rev  2020; 36(7): e3319.
 [http://dx.doi.org/10.1002/dmrr.3319] [PMID: 32233013]

[51]
Bril V, Blanchette CM, Noone JM, Runken MC, Gelinas D, Russell JW. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications  2016; 30(7): 1401-7.
 [http://dx.doi.org/10.1016/j.jdiacomp.2016.05.007] [PMID: 27389526]

[52]
Park HT, Kim YH, Lee KE, Kim JK. Behind the pathology of macrophage-associated demyelination in inflammatory neuropathies: demyelinating Schwann cells. Cell Mol Life Sci  2020; 77(13): 2497-506.
 [http://dx.doi.org/10.1007/s00018-019-03431-8] [PMID: 31884566]

[53]
Koike H, Katsuno M. Macrophages and autoantibodies in demyelinating diseases. Cells  2021; 10(4): 844.
 [http://dx.doi.org/10.3390/cells10040844] [PMID: 33917929]

[54]
Traka M, Podojil JR, McCarthy DP, Miller SD, Popko B. Oligodendrocyte death results in immune-mediated CNS demyelination. Nat Neurosci  2016; 19(1): 65-74.
 [http://dx.doi.org/10.1038/nn.4193] [PMID: 26656646]

[55]
Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: Deciphering a target in inflammatory demyelinating diseases. Front Immunol  2017; 8: 529.
 [http://dx.doi.org/10.3389/fimmu.2017.00529] [PMID: 28533781]

[56]
Skaper SD. Oligodendrocyte precursor cells as a therapeutic target for demyelinating diseases. Prog Brain Res  2019; 245: 119-44.
 [http://dx.doi.org/10.1016/bs.pbr.2019.03.013]

[57]
Höftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol  2020; 139(5): 875-92.
 [http://dx.doi.org/10.1007/s00401-020-02132-y] [PMID: 32048003]

[58]
Velikova TV, Kabakchieva PP, Assyov YS, Georgiev T. Targeting inflammatory cytokines to improve type 2 diabetes control. BioMed Res Int  2021; 2021: 1-12.
 [http://dx.doi.org/10.1155/2021/7297419] [PMID: 34557550]

[59]
Zhou YQ, Liu Z, Liu ZH, et al. Interleukin-6: An emerging regulator of pathological pain. J Neuroinflammation  2016; 13(1): 141.
 [http://dx.doi.org/10.1186/s12974-016-0607-6] [PMID: 27267059]

[60]
Payne SC, Ward G, MacIsaac RJ, Hyakumura T, Fallon JB, Villalobos J. Differential effects of vagus nerve stimulation strategies on glycemia and pancreatic secretions. Physiol Rep  2020; 8(11): e14479.
 [http://dx.doi.org/10.14814/phy2.14479] [PMID: 32512650]

[61]
Caravaca AS, Gallina AL, Tarnawski L, et al. An Effective method for acute vagus nerve stimulation in experimental inflammation. Front Neurosci  2019; 13: 877.
 [http://dx.doi.org/10.3389/fnins.2019.00877] [PMID: 31551672]

[62]
Tsaava T, Datta-Chaudhuri T, Addorisio ME, et al. Specific vagus nerve stimulation parameters alter serum cytokine levels in the absence of inflammation. Bioelectron Med  2020; 6(1): 8.
 [http://dx.doi.org/10.1186/s42234-020-00042-8] [PMID: 32309522]

[63]
Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. The cholinergic anti-inflammatory pathway: A missing link in neuroimmunomodulation. Mol Med  2003; 9(5-8): 125-34.
 [http://dx.doi.org/10.1007/BF03402177] [PMID: 14571320]

[64]
Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci USA  2016; 113(29): 8284-9.
 [http://dx.doi.org/10.1073/pnas.1605635113] [PMID: 27382171]

[65]
Staats P, Giannakopoulos G, Blake J, Liebler E, Levy RM. The use of non-invasive vagus nerve stimulation to treat respiratory symptoms associated with COVID-19: A theoretical hypothesis and early clinical experience. Neuromodulation  2020; 23(6): 784-8.
 [http://dx.doi.org/10.1111/ner.13172] [PMID: 32342609]

[66]
Kaniusas E, Szeles JC, Kampusch S, et al. Non-invasive auricular vagus nerve stimulation as a potential treatment for COVID-19 originated acute respiratory distress syndrome. Front Physiol  2020; 11: 890.
 [http://dx.doi.org/10.3389/fphys.2020.00890] [PMID: 32848845]

[67]
Asad ZUA, Przebinda A, Chaudhary AMD, Farooqui S, Youness H, Stavrakis S. The role of vagus nerve stimulation in sepsis. Bioelectron Med  2020; 3(4): 51-62.
 [http://dx.doi.org/10.2217/bem-2020-0010]

[68]
Boezaart AP, Botha DA. Treatment of Stage 3 COVID-19 with transcutaneous auricular vagus nerve stimulation drastically reduces interleukin-6 blood levels: A report on two cases. Neuromodulation  2021; 24(1): 166-7.
 [http://dx.doi.org/10.1111/ner.13293] [PMID: 33063409]

[69]
Pavlov VA. The evolving obesity challenge: Targeting the vagus nerve and the inflammatory reflex in the response. Pharmacol Ther  2021; 222: 107794.
 [http://dx.doi.org/10.1016/j.pharmthera.2020.107794] [PMID: 33310156]

[70]
Dubin AE, Patapoutian A. Nociceptors: The sensors of the pain pathway. J Clin Invest  2010; 120(11): 3760-72.
 [http://dx.doi.org/10.1172/JCI42843] [PMID: 21041958]

[71]
Muramatsu K. Diabetes mellitus-related dysfunction of the motor system. Int J Mol Sci  2020; 21(20): 7485.
 [http://dx.doi.org/10.3390/ijms21207485] [PMID: 33050583]

[72]
Sung JY, Tani J, Chang TS, Lin CSY. Uncovering sensory axonal dysfunction in asymptomatic type 2 diabetic neuropathy. PLoS One  2017; 12(2): e0171223.
 [http://dx.doi.org/10.1371/journal.pone.0171223] [PMID: 28182728]

[73]
Sohn JW. Ion channels in the central regulation of energy and glucose homeostasis. Front Neurosci  2013; 7: 85.
 [http://dx.doi.org/10.3389/fnins.2013.00085] [PMID: 23734095]

[74]
De Bernardis Murat C, Leão RM. A voltage‐dependent depolarization induced by low external glucose in neurons of the nucleus of the tractus solitarius: interaction with KATP channels. J Physiol  2019; 597(9): 2515-32.
 [http://dx.doi.org/10.1113/JP277729] [PMID: 30927460]

[75]
de Campos Lima T, Santos DO, Lemes JBP, Chiovato LM, Lotufo CMC. Hyperglycemia induces mechanical hyperalgesia and depolarization of the resting membrane potential of primary nociceptive neurons: Role of ATP-sensitive potassium channels. J Neurol Sci  2019; 401: 55-61.
 [http://dx.doi.org/10.1016/j.jns.2019.03.025] [PMID: 31015148]

[76]
Ågren R, Nilsson J, Århem P. Closed and open state dependent block of potassium channels cause opposing effects on excitability-a computational approach. Sci Rep  2019; 9(1): 8175.
 [http://dx.doi.org/10.1038/s41598-019-44564-x] [PMID: 31160624]

[77]
Lin YC, Lin CSY, Chang TS, et al. Early sensory neurophysiological changes in prediabetes. J Diabetes Investig  2020; 11(2): 458-65.
 [http://dx.doi.org/10.1111/jdi.13151] [PMID: 31563156]

[78]
Bönhof GJ, Strom A, Püttgen S, et al. Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. Diabetologia  2017; 60(12): 2495-503.
 [http://dx.doi.org/10.1007/s00125-017-4438-5] [PMID: 28914336]

[79]
Wendelschafer-Crabb G, Kennedy WR, Walk D. Morphological features of nerves in skin biopsies. J Neurol Sci  2006; 242(1-2): 15-21.
 [http://dx.doi.org/10.1016/j.jns.2005.11.010] [PMID: 16448669]

[80]
Cheng HT, Dauch JR, Porzio MT, et al. Increased axonal regeneration and swellings in intraepidermal nerve fibers characterize painful phenotypes of diabetic neuropathy. J Pain  2013; 14(9): 941-7.
 [http://dx.doi.org/10.1016/j.jpain.2013.03.005] [PMID: 23685187]

[81]
Lauria G, Lombardi R, Camozzi F, Devigili G. Skin biopsy for the diagnosis of peripheral neuropathy. Histopathology  2009; 54(3): 273-85.
 [http://dx.doi.org/10.1111/j.1365-2559.2008.03096.x] [PMID: 18637969]

[82]
Galosi E, La Cesa S, Di Stefano G, et al. A pain in the skin. Regenerating nerve sprouts are distinctly associated with ongoing burning pain in patients with diabetes. Eur J Pain  2018; 22(10): 1727-34.
 [http://dx.doi.org/10.1002/ejp.1259] [PMID: 29885017]

[83]
Li S, Liu N, Zhang X, Zhou D, Cai D. Bilinearity in spatiotemporal integration of synaptic inputs. PLOS Comput Biol  2014; 10(12): e1004014.
 [http://dx.doi.org/10.1371/journal.pcbi.1004014] [PMID: 25521832]

[84]
Hao J, Wang X, Dan Y, Poo M, Zhang X. An arithmetic rule for spatial summation of excitatory and inhibitory inputs in pyramidal neurons. Proc Natl Acad Sci USA  2009; 106(51): 21906-11.
 [http://dx.doi.org/10.1073/pnas.0912022106] [PMID: 19955407]

[85]
Moulin TC, Rayêe D, Williams MJ, Schiöth HB. The synaptic scaling literature: A systematic review of methodologies and quality of reporting. Front Cell Neurosci  2020; 14: 164.
 [http://dx.doi.org/10.3389/fncel.2020.00164] [PMID: 32612512]

[86]
Hossain MJ, Kendig MD, Wild BM, et al. Evidence of altered peripheral nerve function in a rodent model of diet-induced prediabetes. Biomedicines  2020; 8(9): 313.
 [http://dx.doi.org/10.3390/biomedicines8090313] [PMID: 32872256]

[87]
Sango K, Mizukami H, Horie H, Yagihashi S. Impaired axonal regeneration in diabetes. perspective on the underlying mechanism from in vivo and in vitro experimental studies. Front Endocrinol  2017; 8: 12.
 [http://dx.doi.org/10.3389/fendo.2017.00012] [PMID: 28203223]

[88]
Sakai J. How synaptic pruning shapes neural wiring during development and, possibly, in disease. Proc Natl Acad Sci USA  2020; 117(28): 16096-9.
 [http://dx.doi.org/10.1073/pnas.2010281117] [PMID: 32581125]

[89]
Faust TE, Gunner G, Schafer DP. Mechanisms governing activity-dependent synaptic pruning in the developing mammalian CNS. Nat Rev Neurosci  2021; 22(11): 657-73.
 [http://dx.doi.org/10.1038/s41583-021-00507-y] [PMID: 34545240]

[90]
Riccomagno MM, Kolodkin AL. Sculpting neural circuits by axon and dendrite pruning. Annu Rev Cell Dev Biol  2015; 31(1): 779-805.
 [http://dx.doi.org/10.1146/annurev-cellbio-100913-013038] [PMID: 26436703]

[91]
Geloso MC, D’Ambrosi N. Microglial Pruning: Relevance for synaptic dysfunction in multiple sclerosis and related experimental models. Cells  2021; 10(3): 686.
 [http://dx.doi.org/10.3390/cells10030686] [PMID: 33804596]

[92]
Plant LD. A role for K2P channels in the operation of somatosensory nociceptors. Front Mol Neurosci  2012; 5: 21.
 [http://dx.doi.org/10.3389/fnmol.2012.00021] [PMID: 22403526]

[93]
Yaron A, Schuldiner O. Common and divergent mechanisms in developmental neuronal remodeling and dying back neurodegeneration. Curr Biol  2016; 26(13): R628-39.
 [http://dx.doi.org/10.1016/j.cub.2016.05.025] [PMID: 27404258]

[94]
Alrabayah M, Qaswal AB, Suleiman A, Khreesha L. Role of potassium ions quantum tunneling in the pathophysiology of phantom limb pain. Brain Sci  2020; 10(4): 241.
 [http://dx.doi.org/10.3390/brainsci10040241] [PMID: 32325702]

[95]
Flor H. Maladaptive plasticity, memory for pain and phantom limb pain: review and suggestions for new therapies. Expert Rev Neurother  2008; 8(5): 809-18.
 [http://dx.doi.org/10.1586/14737175.8.5.809] [PMID: 18457537]

[96]
Meyers EC, Kasliwal N, Solorzano BR, et al. Enhancing plasticity in central networks improves motor and sensory recovery after nerve damage. Nat Commun  2019; 10(1): 5782.
 [http://dx.doi.org/10.1038/s41467-019-13695-0] [PMID: 31857587]

[97]
Schwartzman RJ, Grothusen J, Kiefer TR, Rohr P. Neuropathic central pain: Epidemiology, etiology, and treatment options. Arch Neurol  2001; 58(10): 1547-50.
 [http://dx.doi.org/10.1001/archneur.58.10.1547] [PMID: 11594911]

[98]
Meacham K, Shepherd A, Mohapatra DP, Haroutounian S. Neuropathic pain: Central vs. peripheral mechanisms. Curr Pain Headache Rep  2017; 21(6): 28.
 [http://dx.doi.org/10.1007/s11916-017-0629-5] [PMID: 28432601]

[99]
Drewes AM, Søfteland E, Dimcevski G, et al. Brain changes in diabetes mellitus patients with gastrointestinal symptoms. World J Diabetes  2016; 7(2): 14-26.
 [http://dx.doi.org/10.4239/wjd.v7.i2.14] [PMID: 26839652]

[100]
Selvarajah D, Wilkinson ID, Fang F, et al. Structural and functional abnormalities of the primary somatosensory cortex in diabetic peripheral neuropathy: A multimodal MRI study. Diabetes  2019; 68(4): 796-806.
 [http://dx.doi.org/10.2337/db18-0509] [PMID: 30617218]

[101]
Daffada PJ, Walsh N, McCabe CS, Palmer S. The impact of cortical remapping interventions on pain and disability in chronic low back pain: A systematic review. Physiotherapy  2015; 101(1): 25-33.
 [http://dx.doi.org/10.1016/j.physio.2014.07.002] [PMID: 25442672]

[102]
Vartiainen N, Kirveskari E, Kallio-Laine K, Kalso E, Forss N. Cortical reorganization in primary somatosensory cortex in patients with unilateral chronic pain. J Pain  2009; 10(8): 854-9.
 [http://dx.doi.org/10.1016/j.jpain.2009.02.006] [PMID: 19638329]

[103]
Ferris JK, Peters S, Brown KE, Tourigny K, Boyd LA. Type-2 diabetes mellitus reduces cortical thickness and decreases oxidative metabolism in sensorimotor regions after stroke. J Cereb Blood Flow Metab  2018; 38(5): 823-34.
 [http://dx.doi.org/10.1177/0271678X17703887] [PMID: 28401788]

[104]
Fried PJ, Pascual-Leone A, Bolo NR. Diabetes and the link between neuroplasticity and glutamate in the aging human motor cortex. Clin Neurophysiol  2019; 130(9): 1502-10.
 [http://dx.doi.org/10.1016/j.clinph.2019.04.721] [PMID: 31295719]

[105]
Zhang Y, Qu M, Yi X, et al. Sensorimotor and pain‐related alterations of the gray matter and white matter in type 2 diabetic patients with peripheral neuropathy. Hum Brain Mapp  2020; 41(3): 710-25.
 [http://dx.doi.org/10.1002/hbm.24834] [PMID: 31663232]

[106]
Koike H, Katsuno M. Pathophysiology of chronic inflammatory demyelinating polyneuropathy: Insights into classification and therapeutic strategy. Neurol Ther  2020; 9(2): 213-27.
 [http://dx.doi.org/10.1007/s40120-020-00190-8] [PMID: 32410146]

[107]
Lund JP, Donga R, Widmer CG, Stohler CS. The pain-adaptation model: A discussion of the relationship between chronic musculoskeletal pain and motor activity. Can J Physiol Pharmacol  1991; 69(5): 683-94.
 [http://dx.doi.org/10.1139/y91-102] [PMID: 1863921]

[108]
Hodges PW, Moseley GL. Pain and motor control of the lumbopelvic region: Effect and possible mechanisms. J Electromyogr Kinesiol  2003; 13(4): 361-70.
 [http://dx.doi.org/10.1016/S1050-6411(03)00042-7] [PMID: 12832166]

[109]
Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J  2006; 82(964): 95-100.
 [http://dx.doi.org/10.1136/pgmj.2005.036137] [PMID: 16461471]

[110]
Henry DE, Chiodo AE, Yang W. Central nervous system reorganization in a variety of chronic pain states: A review. PM R  2011; 3(12): 1116-25.
 [http://dx.doi.org/10.1016/j.pmrj.2011.05.018] [PMID: 22192321]

[111]
Sweetnam D, Holmes A, Tennant KA, et al. Diabetes impairs cortical plasticity and functional recovery following ischemic stroke. J Neurosci  2012; 32(15): 5132-43.
 [http://dx.doi.org/10.1523/JNEUROSCI.5075-11.2012] [PMID: 22496559]

[112]
Andersen H. Motor neuropathy. In: Elsevier BV, Ed. Diabetes and the Nervous System 3rd series.   2014; pp. 81-95.
 [http://dx.doi.org/10.1016/B978-0-444-53480-4.00007-2]

[113]
Morgalla MH, de Barros Filho MF, Chander BS, Soekadar SR, Tatagiba M, Lepski G. Neurophysiological effects of Dorsal Root Ganglion Stimulation (DRGS) in pain processing at the cortical level. Neuromodulation  2019; 22(1): 36-43.
 [http://dx.doi.org/10.1111/ner.12900] [PMID: 30561852]

[114]
Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: An update. Am Fam Physician  2016; 94(3): 227-34.
 [PMID: 27479625]

[115]
Weintraub MI, Cole SP. Pulsed magnetic field therapy in refractory neuropathic pain secondary to peripheral neuropathy: electrodiagnostic parameters-pilot study. Neurorehabil Neural Repair  2004; 18(1): 42-6.
 [http://dx.doi.org/10.1177/0888439003261024] [PMID: 15035963]

[116]
Lei T, Jing D, Xie K, et al. Therapeutic effects of 15 Hz pulsed electromagnetic field on diabetic peripheral neuropathy in streptozotocin-treated rats. PLoS One  2013; 8(4): e61414.
 [http://dx.doi.org/10.1371/journal.pone.0061414] [PMID: 23637830]

[117]
Berger P, Landau S. Can an electrical pulsed radio frequency device relieve pain and improve function in patients with pedal diabetic neuropathy? A single blind randomized placebo-controlled trial. Johannesburg.  2016.

[118]
Goroszeniuk T, Kothari S. External stimulation: simplistic solution to intractable pain. London 2015.

[119]
Weintraub MI, Herrmann DN, Smith AG, Backonja MM, Cole SP. Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: A randomized controlled trial. Arch Phys Med Rehabil  2009; 90(7): 1102-9.
 [http://dx.doi.org/10.1016/j.apmr.2009.01.019] [PMID: 19577022]

[120]
Liu H, Zhou J, Gu L, Zuo Y. The change of HCN1/HCN2 mRNA expression in peripheral nerve after chronic constriction injury induced neuropathy followed by pulsed electromagnetic field therapy. Oncotarget  2017; 8(1): 1110-6.
 [http://dx.doi.org/10.18632/oncotarget.13584] [PMID: 27901476]

[121]
Battecha K. Efficacy of pulsed electromagnetic field on pain and nerve conduction velocity in patients with diabetic neuropathy. Bull Fac Phys Ther  2017; 22(1): 9-14.
 [http://dx.doi.org/10.4103/1110-6611.209877]

[122]
Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis, and treatment options. Pain Med  2008; 9(6): 660-74.
 [http://dx.doi.org/10.1111/j.1526-4637.2007.00347.x] [PMID: 18828198]

[123]
Shillo P, Sloan G, Greig M, et al. Painful and painless diabetic neuropathies: What is the difference? Curr Diab Rep  2019; 19(6): 32.
 [http://dx.doi.org/10.1007/s11892-019-1150-5] [PMID: 31065863]

[124]
Baskozos G, Themistocleous AC, Hebert HL, et al. Classification of painful or painless diabetic peripheral neuropathy and identification of the most powerful predictors using machine learning models in large cross-sectional cohorts. BMC Med Inform Decis Mak  2022; 22(1): 144.
 [http://dx.doi.org/10.1186/s12911-022-01890-x] [PMID: 35644620]

[125]
Llorián-Salvador M, González-Rodríguez S. Painful understanding of VEGF. Front Pharmacol  2018; 9: 1267.
 [http://dx.doi.org/10.3389/fphar.2018.01267] [PMID: 30459621]

[126]
Ponirakis G, Abdul-Ghani MA, Jayyousi A, et al. Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control. J Diabetes Investig  2021; 12(9): 1642-50.
 [http://dx.doi.org/10.1111/jdi.13544] [PMID: 33714226]

[127]
Shillo P, Yiangou Y, Donatien P, Greig M, Selvarajah D, Wilkinson ID, et al. Nerve and vascular biomarkers in skin biopsies differentiate painful from painless peripheral neuropathy in type 2 diabetes. Frontiers in Pain Research  2021; 2.

[128]
Herder C, Bongaerts BWC, Rathmann W, et al. Differential association between biomarkers of subclinical inflammation and painful polyneuropathy: results from the KORA F4 study. Diabetes Care  2015; 38(1): 91-6.
 [http://dx.doi.org/10.2337/dc14-1403] [PMID: 25325880]

[129]
Hammi C, Yeung B. StatPearls. Neuropathy 2022.

[130]
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci  2019; 20(6): 1451.
 [http://dx.doi.org/10.3390/ijms20061451] [PMID: 30909387]

[131]
Kaeley N, Ahmad S, Pathania M, Kakkar R. Prevalence and patterns of peripheral neuropathy in patients of rheumatoid arthritis. J Family Med Prim Care  2019; 8(1): 22-6.
 [http://dx.doi.org/10.4103/jfmpc.jfmpc_260_18] [PMID: 30911476]

[132]
Motwani L, Asif N, Patel A, Vedantam D, Poman DS. Neuropathy in human immunodeficiency virus: A review of the underlying pathogenesis and treatment. Cureus  2022; 14(6): e25905.
 [http://dx.doi.org/10.7759/cureus.25905] [PMID: 35844323]

[133]
Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: Epidemiology, pathophysiology and treatment. Drugs  2000; 59(6): 1251-60.
 [http://dx.doi.org/10.2165/00003495-200059060-00005] [PMID: 10882161]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0115733998253213231031050044	Print ISSN 1573-3998
Publisher Name Bentham Science Publisher	Online ISSN 1875-6417
Current Diabetes Reviews

Adaptive Autonomic and Neuroplastic Control in Diabetic Neuropathy: A Narrative Review

Abstract Play Pause

Related Journals

Related Books

Abstract
